Document Detail


First-in-man use of polymer-free valsartan-eluting stents in small coronary vessels: a comparison to polymer-free rapamycin (2%)-eluting stents.
MedLine Citation:
PMID:  19502256     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Orally administered angiotensin receptor antagonists administered after bare-metal stent implantation and even after drug-eluting stent implantation seem to lower in-stent restenosis rates.Whether valsartan-eluting stents are similarly effective was tested here in a first-in-man trial. MATERIALS AND METHODS: The efficacy of a polymer-free drug-eluting stent coated with 300 mcg valsartan was compared to a coating with a 2% rapamycin solution in small (<or= 2.5 mm) coronary vessels with and without oral valsartan on the basis of the YUKON Choice stent system (Translumina GmbH, Hechingen, Germany). Fifteen patients (eight males, mean age 64.4+/-7.7 years) were treated with YUKON Choice valsartan-eluting stents and 30 patients (24 males, mean age 65.7+/-8.4 years) received YUKON Choice rapamycin-eluting stents. Clopidogrel was given for six months in all patients. RESULTS: Within the first 30 days, no adverse events occurred in either group. Binary in-stent restenosis rate was 30.8% (four in 13 angiographic controls) in the valsartan-eluting stent group and 35.0% (eight in 20 angiographic controls) in the rapamycin-eluting YUKON Choice stent group. Mean late lumen loss was 0.78+/-0.53 mm and 0.79+/-0.58 mm, respectively. Target lesion and target vessel revascularisation rate was 26.6% and 25.0%, respectively. No restenoses in rapamycin-eluting YUKON Choice stents appeared in 12 patients with adjunct oral valsartan administration. CONCLUSIONS: If polymer-free YUKON Choice stents are used in small vessels, valsartan-eluting stents show an identical efficacy as rapamycin-loaded stents. In patients with rapamycin-eluting YUKON Choice stents it seems that the efficacy can be increased by oral valsartan administration.
Authors:
Stefan Peters; Boris Behnisch; Torsten Heilmann; Christian Richter
Related Documents :
20657676 - Long-term comparison of balloon angioplasty with provisional stenting versus routine st...
10526046 - Esophageal perforation and mediastinal abscess following placement of a covered self-ex...
9674456 - Experimental study of the histocompatibility of covered expandable metallic stents in t...
20199276 - Adjunctive iliac stents reduce the risk of stent-graft limb occlusion following endovas...
21963266 - Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and ...
8719216 - Experimental reduction of eggshell conductance during incubation. i. effect on the susc...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of the renin-angiotensin-aldosterone system : JRAAS     Volume:  10     ISSN:  1470-3203     ISO Abbreviation:  J Renin Angiotensin Aldosterone Syst     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-06-08     Completed Date:  2009-08-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100971636     Medline TA:  J Renin Angiotensin Aldosterone Syst     Country:  England    
Other Details:
Languages:  eng     Pagination:  91-5     Citation Subset:  IM    
Affiliation:
Klinikum gGmbH Quedlinburg, Cardiology, Germany. ste.peters@asklepios.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Coronary Vessels
Drug-Eluting Stents
Female
Humans
Male
Middle Aged
Sirolimus / administration & dosage
Tetrazoles / administration & dosage*
Valine / administration & dosage,  analogs & derivatives*
Chemical
Reg. No./Substance:
0/Tetrazoles; 137862-53-4/valsartan; 53123-88-9/Sirolimus; 7004-03-7/Valine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Perindopril decreases P wave dispersion in patients with stage 1 hypertension.
Next Document:  Angiotensin-converting enzyme gene insertion/deletion polymorphism in Egyptian patients with myocard...